A Multinational, Multi-Centre, Randomised, Double-Blind, Placebo-Controlled, 3-Way Crossover Study in Migraine Patients, Treated With Two Doses of BGC20-1531 and Placebo.
Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 09 Sep 2016
At a glance
- Drugs AP 1531 (Primary)
- Indications Migraine with aura; Migraine without aura
- Focus Therapeutic Use
- Sponsors BTG; BTG International
- 12 Jan 2016 Status changed from discontinued to withdrawn prior to enrolment as reported by ClinicalTrials.gov.
- 12 Jul 2010 Status changed from not yet recruiting to discontinued as reported by ClinicalTrials.gov.
- 09 Dec 2009 Status changed from planning to not yet recruiting as reported by ClinicalTrials.gov.